Amantadyna

December 7, 2021 Off By maja

Artykuł o amantadynie: nature.com/articles/s4200…


Praca z grupy Nature – https://www.nature.com/articles/s42003-021-02866-9 – powołuje się na wiele prac badawczych. Poniżej dokonamy przeglądu części z tych prac cytowanych w artykule.

  1. „All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study” – ncbi.nlm.nih.gov/pmc/articles/P…
    A w niej czytamy we wnioskach:
https://pbs.twimg.com/media/FFnz1WuXwA4uH92.png

2. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple Sclerosis and Related Disorders. 2020; 42: 102163.

Image

3. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database Syst Rev. 2003:CD003467.

Image

4. Aranda-Abreu GE, Aranda-Martínez JD, Araújo R, Hernández-Aguilar ME, Herrera-Covarrubias D, Rojas-Durán F. Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol Rep. 2020 Oct 10:1–4. doi: 10.1007/s43440-020-00168-1. Epub ahead of print. PMID: 33040252; PMCID: PMC7547815.

Image

5. Fink, K. et al. Amantadine inhibits Sars-Cov-2 in vitrowww.mdpi.com/1999-4915/13/4/539

Image

6. Sarah D. Cady, Klaus Schmidt-Rohr, Jun Wang, Cinque S. Soto, William F. DeGrado & Mei Hong. Structure of the Amantadine Binding Site of Influenza M2 Proton Channels In Lipid Bilayers.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818718/ – praca z laboratorium.

Pozostałe to influenza i ani słowa o SARS-CoV2.

Tak więc – gdzie te rekomendacje? Oparte są na pracy z 22 czy 15 pacjentami?

Autor: Maja Romanowska, Infodemic manager from WHO

Redakcja: Magdalena Gonta-Biernat